SCHEDULE: Deep Track Capital Acquires 3.82% Stake in Personalis

Investment firm Deep Track Capital, through its associated entities, has reported beneficial ownership of 4,000,000 shares, representing 3.82% of Personalis, Inc.'s common stock.

Summary

• Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, have collectively acquired a beneficial ownership of 4,000,000 shares of Personalis, Inc. common stock.
• This holding represents 3.82% of the total outstanding shares.
• The filing is an amendment to a Schedule 13G, indicating a passive investment approach.
• The acquisition date triggering this filing is June 30, 2026.
• The total number of outstanding shares of Personalis, Inc. as of April 29, 2026, was 104,721,098.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not controlling stake acquisition by an investment firm, with no immediate negative implications.

Positives

• Significant investment by a known investment firm (Deep Track Capital) suggests confidence in Personalis, Inc.'s long-term prospects.
• The passive nature of the filing (Schedule 13G) indicates the investment is not intended to influence or control the company's management.
• The reporting entities are established investment vehicles (LP, Master Fund) and an individual with a clear role (Managing Member/Director).

Negatives

• The filing does not provide specific reasons for the investment, leaving the strategic intent open to interpretation.
• A 3.82% stake, while significant, does not grant controlling interest, limiting immediate impact on company direction.

Risks

• Market volatility could impact the value of the investment for Deep Track Capital.
• Changes in Personalis, Inc.'s business performance or strategic direction could negatively affect the investment's value.

Future Outlook

The filing is a Schedule 13G, which is typically filed by passive investors. It does not contain forward-looking statements or specific guidance regarding future actions or performance of Personalis, Inc. The future outlook is therefore not detailed within this document.

Management Comments

• David Kroin, Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, certified that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
• David Kroin, Director for Deep Track Biotechnology Master Fund, Ltd., provided a similar certification.
• David Kroin, as an individual filer, also provided the same certification.

Industry Context

StockSavvy.ai notes that the biotechnology sector often sees significant investment from specialized funds like Deep Track Capital. The acquisition of a substantial minority stake in a company like Personalis, Inc., which operates in the personalized medicine and diagnostics space, is consistent with industry trends of strategic capital allocation towards companies with perceived growth potential in genomics and diagnostics.

Comparison to Industry Standards

• The acquisition of a 3.82% stake is a common threshold for institutional investors to take a significant, yet passive, position in a publicly traded company within the biotechnology sector.
• Companies like BlackRock, Vanguard, and State Street often hold similar or larger passive stakes in established biotechnology firms, indicating this is a standard investment approach.
• The filing does not provide performance data for Deep Track Capital's other investments, making direct comparison of this specific investment's success difficult without further context.

Stakeholder Impact

• Shareholders: May view the investment as a positive signal of institutional confidence, potentially supporting share price, but the passive nature means no immediate strategic shift is expected.
• Management: The passive nature of the investment means no direct pressure on management for immediate changes, but continued performance is expected to maintain investor interest.
• Creditors: No direct impact is anticipated as the filing does not suggest any change in the company's financial structure or debt obligations.

Next Steps

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin will continue to monitor their investment in Personalis, Inc.
• Any future changes in beneficial ownership exceeding reporting thresholds will require further amendments to the Schedule 13G filing.

Key Dates

Recommendation

The filing indicates a significant passive investment by Deep Track Capital, which suggests a belief in Personalis, Inc.'s underlying value. However, as a Schedule 13G filing, it does not provide new operational or strategic information that would warrant a buy or sell recommendation. It confirms an existing or new passive stake, making 'hold' appropriate pending further developments.

Keywords

Personalis, Inc., Deep Track Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Biotechnology, Cayman Islands